ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Scientifically-designed fasting diet lowers risks for major diseases

More evidence for calorie restriction’s longevity effect

Supplementation with vitamin D associated with improved testosterone, erectile function among middle...

A Little Zinc Goes a Long Way

Vitamin D deficiency increases risk of chronic headache

VIDEO: The Best Brain Foods That Help Increase Your Memory!

Get the Most From Your Green Tea

Iron (And More) For Lasting, Natural Energy

Metabolic syndrome increases the need for vitamin E

Supplement combo improves bone density, mood, in postmenopausal women

Print Page
Email Article

Presence of certain tumor markers for melanoma could signal best results for vaccine

  [ 15 votes ]   [ Discuss This Article ] • January 15, 2003

Scientists at the John Wayne Cancer Institute (JWCI) in Santa Monica, California have found a panel of molecular markers that could signal which patients might have the best results following vaccination for malignant melanoma.

According to a study published in the January 15, 2003 issue of Cancer Research, a journal of the American Association for Cancer Research (AACR), the scientists showed that patient survival improved significantly if their tumors expressed higher levels for these markers, known as melanoma-associated antigens (MAAs).

"This investigation has provided a major clue why a certain subset of advanced melanoma patients, about 10 percent of these patients, survive longer than others," said Dr. Dave S. B. Hoon, director of molecular oncology at the JWCI and the study's principal investigator.

"It also indicates that active-specific immunotherapy such as vaccines against melanoma may be particularly effective in this same group of patients."

More than 40,000 new cases and 7,000 deaths will occur this year in the U.S. from melanoma, the most serious form of skin cancer. As such, it is the fifth most common cancer in the nation.

If diagnosed and treated early, the cure rate for melanoma is high. But if it is not removed at an early stage, cancer cells may grow and invade healthy tissue below the skin surface and spread to other parts of the body. The most advanced form of the disease, stage IV tumors that spread to distant organs, has proved resistant to standard treatments of chemo- and radiotherapy. The five-year survival rate among these patients is about five percent.

For this reason, new approaches are under investigation including the use of melanoma vaccines that enhance the body's immune response to specific protein melanoma-associated antigens expressed by tumors.

In their study, funded by the National Institutes of Health and the National Cancer Institute, the JWCI scientists surgically removed tumor samples from 35 late-stage melanoma patients, of which 30 then received immunotherapy with CANVAXIN, a cancer vaccine (CancerVax Corp., of Carlsbad, Calif.).

The tumors subsequently were analyzed for three immunogenic MAAs -- TYR, TRP-2 and MART-1 -- all contained in the cancer vaccine. To assist with their analysis, the scientists turned to a relatively new technique, quantitative reverse-transcriptase Real Time polymerase chain reaction (qRT) analysis – a rapid and highly sensitive procedure invented by Dr. Hoon that magnifies the presence of molecular tumor markers, including these MAAs. Patients were then followed for up to five years to see how their disease progressed.

The results showed that individuals whose tumors have lower expressions for at least two of the MAA markers had a significantly worse prognosis than their counterparts. Conversely, patients with elevated levels for two out of three MAA markers experienced improved survival outcomes.

The JWCI scientists suggested that these antigens enhance the body's immune response to the vaccine, and thus potentially could be used in the clinic to help assess the treatment's likelihood for success.

"It is likely that melanoma cells with decreased expression or loss of MAA are of a selected aggressive phenotype with greater advantage to progress and escape host immunity, thus adversely affecting patients' overall survival," said Dr. Hoon.

"These studies suggest that advanced staged patients with melanomas expressing the two or three of the MAAs would benefit from surgery followed by adjuvant active-specific immunotherapy targeting of these MAAs."

What's more, the results indicate there are potential patients with advanced melanoma disease who can benefit from immunotherapy and that molecular diagnosis can play an integral role in identifying these patients. "The development of molecular stratification factors for specific treatment regimens in malignant melanoma is a major focus of our studies in the molecular oncology department at JWCI," added Dr. Hoon.

Also participating the study were Hiroya Takeuchi, Christine Kuo, Donald L. Morton, and He-Jing Wang, all based at the John Wayne Cancer Institute, St. John's Health Center in Santa Monica.

Founded in 1907, the American Association for Cancer Research (AACR) is a professional society of more than 19,000 laboratory and clinical scientists engaged in cancer research in the United States and more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals (Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention). AACR's annual meeting attracts more than 15,000 participants who share new and significant discoveries in the cancer field, and the AACR's specialty meetings throughout the year focus on all the important areas of basic, translational and clinical cancer research.

Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

NAD+ Ignite with Niagen

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Red Yeast Rice - Natural Option for Supporting Healthy Cholesterol Red Yeast Rice - Natural Option for Supporting Healthy Cholesterol
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map